# EDGAR Filing Document

**Accession Number:** 0001041934
**File Stem:** 0001171843-26-001688
**Filing Date:** 2026-3
**Character Count:** 18355
**Document Hash:** 2bfb900c6a6026dd9687a9e032788941
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-001688.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001171843-26-001688

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 45

**CONFORMED PERIOD OF REPORT**: 20260318

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EDAP TMS SA
- **CENTRAL INDEX KEY:** 0001041934
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29374
- **FILM NUMBER:** 26765290

**BUSINESS ADDRESS:**
- **STREET 1:** PARC D'ACTIVITES LA POUDRETTE LAMARTINE
- **STREET 2:** 4 RUE DU DAUPHINE
- **CITY:** 69120 VAULX EN VELIN
- **STATE:** I0
- **ZIP:** 69120
- **BUSINESS PHONE:** 33672643508

**MAIL ADDRESS:**
- **STREET 1:** PARC D'ACTIVITES LA POUDRETTE LAMARTINE
- **STREET 2:** 4 RUE DU DAUPHINE
- **CITY:** 69120 VAULX EN VELIN
- **STATE:** I0
- **ZIP:** 69120

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

________________________________________________________

**FORM 8-K**

**________________________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 18, 2026**

_________________________________________________________

**EDAP TMS SA**

**(Exact name of registrant as specified in its charter)**

__________________________________________________________

---

| | | |
|:---|:---|:---|
| **France** | **000-29374** | **98-1644844** |
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(I.R.S. Employer Identification No.)** |

---

---

| |
|:---|
| **Parc d'Activites la Poudrette-Lamartine** |
| **4/6, rue du Dauphiné** |
| **Vaulx-en-Velin, France 69120** |
| **(Address of Principal Executive Offices) (Zip Code)** |

---

---

| |
|:---|
| **(+33) 47-215-3150** |
| **(Registrant's telephone number, including area code)** |

---

**(Former name or former address, if changed since last report)**

_________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **American Depositary Shares, each representing one Ordinary Share (Ordinary Shares, nominal value €0.13 per share)** | **EDAP** | **Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

On March 18, 2026, EDAP TMS S.A. (the "Company") will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. A copy of the presentation materials to be used by the Company at the conference is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The presentation will be webcast and may be accessed in the Investors section of the Company's website.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

[99.1](exh_991.htm) [EDAP TMS S.A. Investor Presentation dated March 18, 2026](exh_991.htm) <br> 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: March 18, 2026 | **EDAP TMS S.A.** |
|  | By: <u>/s/ Sanket Shah</u> |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sanket Shah |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General Counsel and Corporate Secretary |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![](exh991_01.jpg)

The Global Leader in Therapeutic Ultrasound 1

![](exh991_02.jpg)

Statements & Disclaimer F O R W A R D - L O O K I N G 2

![](exh991_03.jpg)

Strategic Company Focus 3 Global Leader in Therapeutic Ultrasound for the Treatment of Cancer and Benign Disease

![](exh991_04.jpg)

Large and Growing Market Opportunity In Urology and Prostate Cancer 4

![](exh991_05.jpg)

Prostate Cancer Market Opportunity Number of New Prostate Cancer Cases Region Europe Asia North America Latin America Africa Oceania Total 473,011 386,424 255,782 225,985 103,050 23,602 1,467,854 L A R G E G L O B A L M A R K E T 1.5 Million New Prostate Cancer Cases Per Year Data Source: Cases refers to Diagnosed Cases per year as of 2022 from World Health Organization – Globocan 2022 5

![](exh991_06.jpg)

Focal One Answers an Unmet Need for a Large Underserved Patient Population PR O S T A T E C A N C ER Focal One HIFU Focal One HIFU 6 First - Line Treatment Progression from Active Surveillance Salvage Treatment

![](exh991_07.jpg)

FO C A L O N E® RO B O T I C HI FU Prostate Cancer Patient Value Equation HIGH LOW HIGH Radiation QUALITY OF LIFE PRESERVATION (Urinary and Sexual Function Outcomes) Focal One Robotic HIFU Active Surveillance Surgery PROVEN EFFICACY (Cancer Control) 7

![](exh991_08.jpg)

8 DR I V I N G A P A R A DI G M S H I F T I N P R O S T A T E C A N C E R Focal Therapy \| The New Emerging Market (1) As of 2013. Chen et al. National trends in the management of localized prostate cancer: A population - based analysis 2004 - 2013. Prostate. (2) Source: Internal company management estimates Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Focal Therapy (HIFU) Traditional Market (1) Emerging Market (2) Future Market (2) Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Focal Therapy (HIFU)

![](exh991_09.jpg)

9 0% 20% 40% 60% 80% CAGR (2022 - 2024) DR I V I N G A P A R A DI G M S H I F T I N P R O S T A T E C A N C E R HIFU \| The Fastest Growing Treatment Option Based on Medicare claims data reported by CMS in the HOPPS Final Rules for FY2024 – FY2026.. As CMS publishes claims data on a retrospective basis, the CAGR shown reflects growth over the 2022 – 2024 claims period. HIFU Cryo Brachytherapy Radical Prostatectomy

![](exh991_10.jpg)

10 Focal One® Best - in - Class Technology

![](exh991_11.jpg)

Integrated Workstation Compatible With Standard OR Beds MRI, PSMA PET Unfold AI\* , OnQ Prostate\* Koelis\* and DynaCAD\* 3D Biopsy HIFUsion® Image - Guided Treatment Planning Dynamic Focusing Probe Precise Robotic Positioning Multi - Axis Sub - millimeter Robotic Movements Auto - Adjusting Pinpoint Delivery of HIFU Energy 11 \* Not available in all markets. May require additional purchase The Most Advanced Robotic HIFU Platform Controlled by Urologists • Expanded HIFUsion® Capabilities • Streamlined Treatment Workflows • Embedded Video Content Library • Treatment Streaming and Recording\* • Remote Proctoring & Telecollaboration\* • Endometriosis Treatment Ready\*

![](exh991_12.jpg)

![](exh991_13.jpg)

Robotics HIFU Advanced Imaging Focal One® Core Technologies Artificial Intelligence (AI) Remote Connectivity 13

![](exh991_14.jpg)

Strong Supporting Clinical Evidence 14

![](exh991_15.jpg)

Proven Clinical Evidence Supporting Focal One Robotic HIFU 3. Preserve Sexual Function 2. Maintain Urinary Control 1. Cancer Control 1000+ Peer - Reviewed Publications Supporting HIFU in the Treatment of Prostate Cancer (1) Optimizing Trifecta Outcomes for Prostate Cancer (1) PubMed Database search of "HIFU Prostate Cancer" Functional Outcomes 15 15

![](exh991_16.jpg)

16 CANCER CONTROL PATIENT BURDEN Treatment Comparison Focal One HIFU Provides the Optimal Organ - Preserving Patient Treatment ORGAN - PRESERVING STRATEGY WHOLE - GLAND RADICAL TREATMENT STRATEGY QUALITY OF LIFE FUNCTIONAL OUTCOMES 96% (3) Continence Preservation 82% (3) Erectile Function Preservation - Ejaculation Preservation Low Risk of Complications - Typical Complications - Treatment Process Active Surveillance N/A 10 - year Cancer Specific Survival (\*) Hospital stay duration for radical prostatectomy may vary (1) Yeh, HT et al. 10 - year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang Gung research database (CGRD) study with inverse - probability - of - treatment weighting (IPTW) analysis. Int Urol Nephrol (2025). (2) Stensland KD et al. National Long - term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2024 Feb;184:135 - 141. (3) Donovan JL, et al. Patient - Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016 Oct 13. (4) Sullivan JF et al. Ejaculation profiles of men following radiation therapy for prostate cancer. J Sex Med. 2013 May;10(5):1410 - 6. (5) Arnouil, N., et al. "Traitement focal par HIFU versus prostatectomie radicale robot - assistée pour cancer de la prostate localisé: résultats carcinologiques et fonctionnels à 1 an." Progrès en Urologie 28.12 (2018): 603 - 610. (6) von Hardenberg J et al. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS - fusion control biopsies: A prospective evaluation. Urologic Oncology: Seminars and Original Investigations, Volume 36, Issue 9, 2018, Pages 401.e1 - 401.e9 75% (3) 96% (3) 98% (5) 69% (3) 49% (3) 93% (5) 0% 28% (4) 96% (6) High Medium Low Blood Loss and Other Surgical Complications Radiation Toxicity, Risk of Secondary Cancers - 1 Session 1 - Day Hospital Stay (\*) 45 Sessions 45 Visits 1 Session, Same Day Outpatient Procedure Radiation Surgery Radical Prostatectomy Focal One® Robotic HIFU 99% (2) 91% (1) 95% (1)

![](exh991_17.jpg)

17 HIFI - Prospective Multicentric Comparative Study Focal One® HIFU vs Radical Prostatectomy Prospective, Comparative, Multicentric , non - inferiority clinical trial comparing HIFU to Radical Prostatectomy (RP) 3,328 patients treated (1,967 HIFU - 1,361 RP) across 46 centers 90% of HIFU patients treated with Focal One Comparable Cancer Control (Primary Endpoint): 90% STFS for HIFU vs 86% for RP; p = 0.008 Superior functional outcomes for HIFU (Secondary Endpoint): • Urinary Continence significantly better after HIFU • Significantly lower stress incontinence after HIFU • Erectile Function less impaired Published in European Urology – December 2024 Ploussard et al. "Whole - gland or Subtotal High - intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial." European urology vol. 87,5 (2025): 526 - 533. doi:10.1016/j.eururo.2024.11.006

![](exh991_18.jpg)

18 FARP - Randomized Controlled Trial Focal Ablation vs Radical Prostatectomy Randomized Controlled, Non - inferiority Clinical Trial comparing Focal Ablation (FA) to Robot - Assisted Radical Prostatectomy (RP) Equivalent Oncologic Control at 3 years (93.5% TFF vs 91.5%) Superior Functional Outcomes after Focal Ablation 213 Patients included in the Clinical Trial 25% of Patients refused radical surgery after randomized to RP and opted for FA 80+% of Focal Ablation patients treated with Focal One® Baco et al. Final, three - year oncological results of a randomized clinical trial FARP comparing Focal Ablation and Radical Prostatectomy in patients with unilateral clinically - significant prostate cancer. Journal of Urology [Internet]. 2025 May 1;213(5S):e714. Baco et al. Focal Ablation Versus Radical Prostatectomy for Intermediate - Risk Prostate Cancer: Interim Analysis of a Randomized Controlled Trial. The Journal of Urology. Vol. 206, No. 3S, Supplement, Sunday, September 12, 2021 Final Results Presented at AUA 2025 0% 20% 40% 60% 80% 100% Oncologic Control (ITT Treatment Failure Free) Continence (Pad - free) Erectile Function Preservation Surgery Ultrasound Focal Ablation Surgery Ultrasound Focal Ablation Surgery Ultrasound Focal Ablation OP T I M A L T R I F E C T A OUT C OM E S

![](exh991_19.jpg)

19 HIFU Demonstrates Equivalent 10 - year Survival to Radiation Therapy 10 - year Oncological Outcomes of HIFU vs EBRT (1) • Lower Mortality at 10 years post HIFU (9.2%) compared to EBRT (16.7%) • Lower Cancer - Specific Mortality after HIFU (5.4%) compared to EBRT (9.2%) Radiation HIFU HIFU Radiation 80% 85% 90% 95% Overall Survival Cancer - Specific Survival Yeh, HT., Liu, YY., Chang, Y.L. et al. 10 - year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang Gung research database (CGRD) study with inverse - probability - of - treatment weighting (IPTW) analysis. Int Urol Nephrol (2025). https://doi.org/10.1007/s11255 - 025 - 04805 - 7

![](exh991_20.jpg)

Strong Hospital and Physician Reimbursement 20

![](exh991_21.jpg)

Environment for Growth ST R O N G R E I MBU R SE ME N T Creates Favorable 1. APC Level 6 Under CMS for CY23, CY24 and CY25 2. 90% Increase in Reimbursement in 2023 3. APC Level 6 Maintained by CMS in 2026 Based on CMS Hospital Outpatient Prospective Payment System Final rule 21

![](exh991_22.jpg)

Hospital Outpatient Medicare Payment 2026 Payment CPT® Code Procedure $5,478 55875 Prostate Brachytherapy $9,671 55873 Cryo Ablation +4.3% $9,671 55880 HIFU $10,860 55866 Laparoscopic/Robotic Prostatectomy (Medicare Payment (National Average). From CMS Hospital Outpatient Prospective Payment System – CY25 and CY26 Final rule 22

![](exh991_23.jpg)

Favorable Physician Payment Physician Payment (Medicare - 2026) Work RVU (2026) CPT® Code Procedure $693 13.12 55875 Prostate Brachytherapy $692 13.26 55873 Cryo $530 11.21 55882 MRI Transurethral Ultrasound Ablation $884 17.29 55880 HIFU Laparoscopic/Robotic Prostatectomy 55866 21.90 $1,087 Based on CMS Physician Fee Schedule – CY 2026 Final rule 23

![](exh991_24.jpg)

Growing Global Install Base 24

![](exh991_25.jpg)

FO CA L O NE A D O P T I O N A CCE L E R A T I NG At Major U.S. Hospitals 87 Focal One Systems as of Dec. 31, 2025 (42 Academic – 45 Community)

![](exh991_26.jpg)

Strong Adoption by the Highest Ranked Prostate Cancer Hospitals in the US FO C A L O N E I S T H E L E A D I N G FO C A L T H E RA P Y T E C H N O L O G Y 70% 7 Out of 10 Best Hospitals for Urology National Comprehensive Cancer Network® 55% 18 Out of 33 NCCN Member Institutions 63% 22 Out of 35 SUO Approved Programs 26

![](exh991_27.jpg)

FOCAL ONE FIXED SITES FOCAL ONE MOBILE SITES 41 Focal One Systems as of Dec. 31, 2025 254 Focal One Treatment Clinical Sites FO CA L O NE A D O P T I O N A CCE L E R A T I NG At Major European Hospitals

![](exh991_28.jpg)

Key Business Trends 28

![](exh991_29.jpg)

29 2021 2022 2023 2024 2025 Focal One U.S. Momentum 2021 - 2025 (Compounded Annual Growth Rates) Focal One Procedures CAGR 29 Focal One Installations CAGR 44% 52% Focal One Procedures Focal One Installations

![](exh991_30.jpg)

30 30 2021 2022 2023 2024 Focal One HIFU Accelerated Revenue Growth Capital Sale + Recurring Revenue Capital Sales Disposables & Treatment - Driven Revenue Service (1) 2025 ANNUAL HIFU REVENUE (1) Based on preliminary, unaudited Company results for 2025 (2) Source: 2026 financial guidance as disclosed in the Company's preliminary, unaudited earnings release (as of January 12, 2026) (2) 2026

![](exh991_31.jpg)

31 HIFU Unlocks a Large Market Opportunity (1) Newly Diagnosed Cases per year From World Health Organization – Globocan 2022 (2) From WHO and Habib N et al. Bowel Endometriosis: Current Perspectives on Diagnosis and Treatment. Int J Womens Health. 2020 (3) Xu et al.. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Mens Health. 2021 (4) Based on UN Population Division and Goehring et al. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev. 1997 (5) Based on UN Population Division and Bomeli et al. Evaluation of a thyroid nodule. Otolaryngol Clin North Am. 2010 20.5 M (2) Rectal Endometriosis 1.5 M Prostate Cancer (1) 11.3 M (3) BPH (Benign Prostatic Hyperplasia) 510,992 (1) Pancreatic Cancer 866,136 (1) Liver Cancer 51.4 M (5) Thyroid Nodules 2.3 M (1) Breast Cancer 8.3 M (4) Breast Fibroadenoma

![](exh991_32.jpg)

Positioned for Growth SU MMA R Y • Large Addressable Markets in Men's and Women's Health • Growing Global Install Base of Leading Tier 1 Academic and Community Hospitals • Differentiated Non - Invasive Robotic HIFU Technology Solving Unmet Needs for Prostate Cancer, BPH and Endometriosis • Strong Clinical Evidence with Favorable Reimbursement in Place • Proven Management Team from Industry - Leading MedTech Companies 32

![](exh991_33.jpg)

The Global Leader in Therapeutic Ultrasound 33

------